Longevity movement grows, but society lags behind

In his conversation with Lifespan.io, Cian describes how he adjusted his strategy over the past year. Pushing radical life extension directly meets resistance from governments, investors, and the general public. But preventive medicine, encompassing healthy lifestyles, personalised diagnostics, and targeted supplementation, finds broad support. His reasoning: if that movement becomes large enough, a small fraction of the capital flowing into it can be redirected toward genuine aging biotechnology.

The detour as strategy

Cian uses the metaphor of a river: it reaches the sea not in a straight line but via the path of least resistance. He describes how governments support preventive medicine because it can reduce healthcare costs, and how investors are pouring in capital at scale. Even a small percentage of that capital, he argues, would be sufficient to fund aging research at a scale currently out of reach.

This is not scientific research but a strategic perspective from a longevity entrepreneur. It does illustrate a genuine tension in the field: the science is running ahead of what society is ready to accept and fund.

Relevance for the longevity field

The debate about how to anchor longevity science in society is real and growing. Platforms like the 2060 Forum connect scientists, investors, and policymakers across Europe. Whether the chosen strategy succeeds remains to be seen. Cian himself acknowledges that 2060 is an ambitious deadline, but defends it as a necessary source of urgency. The challenge is not only biological but also cultural: treating aging as a treatable condition requires a shift in how societies relate to illness, death, and the distribution of quality of life.

Read the original article